Evidence map›Paper›PMID 26938529›Full record

ArticleInternational journal of molecular sciences2016

Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).

Ralph A Pietrofesa, Anastasia Velalopoulou, Steven M Albelda, Melpo Christofidou-Solomidou

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ralph A PietrofesaDivision of Pulmonary, Allergy, and Critical Care Medicine and the Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3615 Civic Center Boulevard, Abramson Research Center, Office Suite 1016C, Philadelphia, PA 19104, USA. ralphp@mail.med.upenn.edu.
Anastasia VelalopoulouDivision of Pulmonary, Allergy, and Critical Care Medicine and the Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3615 Civic Center Boulevard, Abramson Research Center, Office Suite 1016C, Philadelphia, PA 19104, USA. avela@mail.med.upenn.edu.
Steven M AlbeldaDivision of Pulmonary, Allergy, and Critical Care Medicine and the Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3615 Civic Center Boulevard, Abramson Research Center, Office Suite 1016C, Philadelphia, PA 19104, USA. albelda@mail.med.upenn.edu.
Melpo Christofidou-SolomidouDivision of Pulmonary, Allergy, and Critical Care Medicine and the Department of Medicine, University of Pennsylvania Perelman School of Medicine, 3615 Civic Center Boulevard, Abramson Research Center, Office Suite 1016C, Philadelphia, PA 19104, USA. melpo@mail.med.upenn.edu.
University of Pennsylvania · US

Funding

Translational Research Support CoreP30ES013508 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Rebecca A Simmons · 2006 to 2026
$35.3M
Environmental Science Project 3 - Social Determinants of Risk and Attitudes AboutP42ES023720 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER · 2014 to 2018
$11.3M
Secoisolariciresinol Diglucoside (SDB) Protection in Radiation PheumonopathyR01CA133470 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTOFIDOU-SOLOMIDOU, MELPO · 2008 to 2012
$2.2M
NOVEL SYNTHETIC SDG TO TREAT TRAUMA-INDUCED INFLAMMATIONR21AT008291 · NCCIH · UNIVERSITY OF PENNSYLVANIA · PI CHRISTOFIDOU-SOLOMIDOU, MELPO, WINKELSTEIN, BETH A · 2015 to 2016
$440k
Mesothelioma inhibition by secoisolariciresinol diglucoside (SDG)R03CA180548 · NCI · UNIVERSITY OF PENNSYLVANIA · PI CHRISTOFIDOU-SOLOMIDOU, MELPO · 2013 to 2014
$137k
NCCIH NIH HHS 1R21AT008291-02NCCIH NIH HHS R21 AT008291NCI NIH HHS R01 CA133470NCI NIH HHS R03 CA180548NIEHS NIH HHS 1P30 ES013508-02NIEHS NIH HHS 1P42ES023720-01NIEHS NIH HHS P30 ES013508NIEHS NIH HHS P42 ES023720
6 · The paper itself

Abstract

The interaction of asbestos fibers with macrophages generates harmful reactive oxygen species (ROS) and subsequent oxidative cell damage that are key processes linked to malignancy. Secoisolariciresinol diglucoside (SDG) is a non-toxic, flaxseed-derived pluripotent compound that has antioxidant properties and may thus function as a chemopreventive agent for asbestos-induced mesothelioma. We thus evaluated synthetic SDG (LGM2605) in asbestos-exposed, elicited murine peritoneal macrophages as an in vitro model of tissue phagocytic response to the presence of asbestos in the pleural space. Murine peritoneal macrophages (MFs) were exposed to crocidolite asbestos fibers (20 µg/cm²) and evaluated at various times post exposure for cytotoxicity, ROS generation, malondialdehyde (MDA), and levels of 8-iso Prostaglandin F2α (8-isoP). We then evaluated the ability of LGM2605 to mitigate asbestos-induced oxidative stress by administering LGM2605 (50 µM) 4-h prior to asbestos exposure. We observed a significant (p < 0.0001), time-dependent increase in asbestos-induced cytotoxicity, ROS generation, and the release of MDA and 8-iso Prostaglandin F2α, markers of lipid peroxidation, which increased linearly over time. LGM2605 treatment significantly (p < 0.0001) reduced asbestos-induced cytotoxicity and ROS generation, while decreasing levels of MDA and 8-isoP by 71%-88% and 41%-73%, respectively. Importantly, exposure to asbestos fibers induced cell protective defenses, such as cellular Nrf2 activation and the expression of phase II antioxidant enzymes, HO-1 and Nqo1 that were further enhanced by LGM2605 treatment. LGM2605 boosted antioxidant defenses, as well as reduced asbestos-induced ROS generation and markers of oxidative stress in murine peritoneal macrophages, supporting its possible use as a chemoprevention agent in the development of asbestos-induced malignant mesothelioma.

Indexed as

Oxidative StressAnimalsAntioxidantsAsbestosButylene GlycolsCells, CulturedGlucosidesMacrophages, PeritonealMiceNF-E2-Related Factor 2Signal TransductionAntioxidantsAsbestosButylene GlycolsGlucosidesNfe2l2 protein, mouseNF-E2-Related Factor 2secoisolariciresinol diglucosideantioxidantasbestosLGM2605lignanmacrophagemesotheliomaoxidative stressphase II enzymesreactive oxygen speciessecoisolariciresinol diglucoside

Identifiers

PMID26938529
PMCPMC4813184
OpenAlexW2292886889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.